Haemonetics Corporation
Roy Galvin (EVP, Chief Commercial Officer) reports HAE insider transactions
About this filing
Haemonetics Corporation (HAE) filed Form 4 (insider transaction) with the SEC on Nov 3, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Roy Galvin · EVP, Chief Commercial Officer
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | F · tax withholdingFootnotes F1, F2 | −146 | $119.65 | $17,468.90 | 39,805 | Direct |
Footnotes
- F1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
- F2 This number includes unvested RSUs previously reported as well as 69 shares acquired by the reporting person under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time) on October 31, 2026.
More HAE filings
- 10-Q
Filed Nov 5, 2026
- 8-K
Filed Nov 5, 2026
- 8-K
Filed Oct 8, 2026
- 8-K
Filed Aug 18, 2026
- SC 13G/A
Filed Aug 12, 2026
- S-8
Filed Aug 6, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.